Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Aberrant Methylation of p16INK4a in Anatomic and Gender-specific Subtypes of Sporadic Colorectal Cancer

John K. Wiencke, Shichun Zheng, Amalia Lafuente, Maria Jose Lafuente, Corita Grudzen, Margaret R. Wrensch, Rei Miike, Antonio Ballesta and Manuel Trias
John K. Wiencke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shichun Zheng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amalia Lafuente
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Jose Lafuente
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corita Grudzen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margaret R. Wrensch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rei Miike
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Ballesta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Trias
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published June 1999
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Colorectal cancer (CRC) occurring in the proximal colon and among women may represent a distinct subtype of the disease. In the present study of 120 sporadic CRCs, we used methylation-specific PCR to test whether methylation of the CpG island in the 5′ region of the p16INK4a tumor suppressor gene was associated with anatomical location, gender, or other clinicopathological characteristics. Overall, 18.3% of the tumors had detectable p16INK4a methylation. A marked preponderance of methylated tumors occurred within the proximal colon; cancers occurring proximal to the sigmoid colon were 13.1 times more likely to contain methylated p16INK4a compared with distal tumors. In addition, female patients were 8.8 times more likely than males to have methylation-positive cancers, and p16INK4a methylation was also associated with poorly differentiated tumors. The localization of tumors with p16INK4a methylation within the proximal colon and among female patients specifically adds to a growing database of molecular alterations that define important subtypes of sporadic CRC. The potentially reversible nature of CpG methylation may provide novel therapeutic opportunities for this increasing subtype of the disease, which, due to anatomical location, presents a great challenge for early detection.

Introduction

CRC3 is the third most common form of internal malignancy in Westernized countries. In the United States, 143,000 people were diagnosed with CRC in 1995 ,(1 , 2) . Epidemiological studies of migrant populations show that environmental factors play an important role in the etiology of this form of cancer. Persons migrating from low to high CRC risk countries acquire the risks of the high-risk population within a single generation (3 , 4) . The incidence of CRC worldwide is very dynamic; CRC rates are increasing in traditionally low-risk countries that are adopting a globalized Western-style diet high in fat and meat protein and low in fiber, vegetables, and fruit (5) and a more sedentary lifestyle. Within high-risk countries such as the United States, CRC rates are rising rapidly among African-American (6) , Hispanic, and American Indian populations (7) . Whereas a dominant role has been ascribed to diet and lifestyle in the etiology of CRC, a striking and perplexing aspect of the epidemiology of CRC is the variation in risk associated with gender and anatomical location. Numerous studies have implicated hormonal and reproductive influences in the etiology of CRC in women (5) . Recent examples include studies that found reduced risks for CRC (8 , 9) and adenomatous polyps (10 , 11) in women receiving postmenopausal hormone replacement therapy. Moreover, a female excess of right-sided CRC at all ages and an excess of left-sided cancers among males have been documented repeatedly (12, 13, 14, 15) . These gender associations with anatomical subsite parallel the risk observed in low- versus high-risk countries (16) . A notable feature of the abovementioned increase in CRC within United States minority groups is the pronounced increase in right-sided CRC among older women (6 , 7) . These observations indicate differential environmental influences in women and men and in specific locations in the large bowel. The role of female hormones and their effects on bile acid metabolism were previously proposed to explain gender influences on the anatomical subsite distribution of CRC (17 , 18) .

Creating an etiological model of CRC that integrates these epidemiological features of the disease with the manifold molecular and genetic aspects of CRC that have recently been discovered is a formidable challenge. The well-described model of colorectal carcinogenesis envisions a stepwise accumulation of early and late genetic alterations in the progression of adenoma to carcinoma (19) . Epidemiological clues to the etiology of CRC have been sought by studying the mutational patterns within these loci (e.g., the p53 gene; Ref. 20 ). Identification of mutations within the familial APC (21) and within HNPCC genes (22) has helped to explain the inherited forms of CRC. Interestingly, loci involved in the heritable forms of CRC may also be altered somatically in sporadic CRC (23) , providing a mechanistic bridge between familial and sporadic CRC.

In addition to mutational changes, epigenetic mechanisms play a prominent role in CRC. Aberrant DNA methylation has long been noted in colorectal carcinogenesis; imbalances in methylation are thought to occur early in the process and are characterized by genome-wide hypomethylation and regional and locus-specific hypermethylation (24) . Among the common targets for aberrant DNA methylation is the 5′ region of the p16INK4a tumor suppressor gene (25 , 26) . The p16INK4a protein plays an important role in the passage of cells through the G1 phase of the cell cycle by binding to cyclin-dependent kinases and inhibiting their interaction with cyclin D1 and reducing phosphorylation of the retinoblastoma protein (pRB; Ref. 27 ). Methylation of cytosine residues at CpG sites in p16INK4a is common in CRC cell lines and is associated with transcriptional silencing of the gene (28 , 29) . Epigenetic alterations that suppress gene expression are potentially reversible, offer unique opportunities for the development of new therapies, and could also be the focus of preventive strategies.

In the present study, we measured the occurrence of p16INK4a methylation in primary CRCs using a recently developed MSPCR method and explored the relationship of methylation to demographic and clinicopathological characteristics of the patients. Because of the known epidemiological correlates of gender and anatomical location, we stratified our population by gender and location to test whether p16INK4a methylation is involved in a unique pathway for CRC development.

Materials and Methods

Patient Population and Clinicopathological Information.

Patients were ascertained through the University of Barcelona Hospital Clinic. The Hospital Clinic is a 900-bed institution with about 33,000 patient admissions per year and serves a source population of approximately 600,000 inhabitants of Catalonia, Spain. The Hospital Clinic is a teaching institution and tertiary care facility. During 1996–1997, 275 consecutive CRC patients undergoing surgery were identified through the clinic’s two surgical services as potential subjects for a hospital-based case-control study of CRC. Patients who were ≥35 years of age and <90 years were invited to participate in the study. Eighteen subjects refused to participate, leaving a total of 249 enrolled subjects (132 men and 117 women). A consecutive case-series subset of 120 patients within one surgical service also provided tissue specimens (uninvolved colon and tumor) for the current molecular study. Patients provided signed informed consent; all procedures were approved by the Hospital Clinic’s institutional review board (Comite Etico de Investigacion Clinica).

Primary tumors were surgically dissected and immediately frozen at −80°C. A questionnaire was administered to each patient by an interviewer; the questionnaire elicited demographic information and data on occupation, diet, and personal medical history. Clinicopathological data were collected and merged with patient questionnaires. A modified version of the Dukes’ staging system was used. Surgical records identified eight subsites: (a) cecum; (b) ascending colon; (c) transverse colon; (d) descending colon; (e) sigmoid colon; (f) rectosigmoid junction; (g) rectum; and (h) anal canal. Proximal tumors were defined as including the right side of the colon and descending colon up to the sigmoid colon. Additional analyses were carried out that included the transverse and descending colon tumors with the distal category of CRCs.

DNA was isolated from tumor specimens using standard methods involving RNase, proteinase K, chloroform/isoamyl alcohol extraction, and ethanol precipitation. DNA was quantitated by Hoescht 33258 fluorometry (Hoeffer Scientific).

MSPCR.

Detection of methylated CpG sites within the 5′ region of the p16INK4a gene was carried out using MSPCR (30 , 31) . Briefly, 1.0 μg of purified DNA was diluted in 36 μl of H20 to which 4 μl of 3.0 m NaOH were added, and DNA was denatured at 37°C for 15 min. The sample was then treated with 416 μl of 3.6 m sodium bisulfite solution (pH 5.0) and 24 μl of 10 mm hydroquinone. Both bisulfite and hydroquinone solutions were prepared fresh for each analysis. Samples were incubated at 55°C for 16 h; 100 μl of mineral oil were layered on top of the solution to prevent evaporation. After incubation, the solution was cooled to −80°C for 10 min, after which the unfrozen mineral oil was removed without disturbing the bisulfite-DNA solution.

Bisulfite-modified DNA was purified with the Wizard DNA Clean-UP System and Vacuum Manifold (Promega), according to the manufacturer’s instructions. DNA was eluted twice with a total volume of 100 μl of 10 mm Tris-1 mm EDTA buffer (pH 7.8). The final step of the cytosine to uracil conversion reaction was achieved with alkali treatment (NaOH, final concentration = 0.3 m) at 37°C for 15 min followed by ammonium acetate (pH 7.0; final concentration, 3.0 m) neutralization and ethanol precipitation. For each set of tumors assayed, two cell line DNA samples were also treated with bisulfite and amplified by MSPCR. Both a methylation-positive CRC cell line (SW-480; American Type Culture Collection) and a methylation-negative cell line (SK-N-SH; American Type Culture Collection) served as controls for the bisulfite conversion, DNA recovery, and PCR reactions.

For each tumor, a multiplex PCR amplification of bisulfite-treated DNA was carried out with primers (Life Technologies, Inc.) specific for methylated (M primer) and nonmethylated (U primer) CpG sites within the p16INK4a promoter region (31) ; (M primer, 5′-TTATTAGAGGGTGGGGCGGATCGC and 5′-GACCCCGAACCGCGACCGTAA), and nonmethylated (U2 primer, 5′-TTATTAGAGGGTGGGGTGGATTGT and 5′-CCACCTAAATCAACCTCCAACCA). The PCR mixture contained GeneAmp PCR buffer (Perkin-Elmer Corp.), MgCl2 (1.5 mm), deoxynucleotide triphosphates (200 μm each), primers (0.4 μm for each primer), modified DNA templates (50 ng), and 2.5 Units of AmpliTaq (Perkin-Elmer Corp.) in a total volume of 50 μl. The PCR reaction was repeated for 35 cycles on a GeneAmp 9600 thermal cycler (Perkin-Elmer Corp.) under the following conditions: preheat at 94°C for 1 min, 94°C for 30 s, 65°C for 10 s, 72°C for 30 s, and a final extension at 72°C for 10 min. Aliquots (15 μl) of PCR products were loaded onto 2.5% agarose gels, stained with ethidium bromide, and visualized under UV light.

To confirm the specificity of the method, PCR product from the positive and negative controls and several CRC tumor specimens were sequenced using purified PCR product and an ABI 377 automated sequencer with dye primer chemistry. To assess the sensitivity of the MSPCR method, methylated and unmethylated cell line DNA samples were mixed in different ratios; a single unambiguous p16INK4a methylated band was detectable when methylated template was present at greater than 1:32 (3%) of the total DNA. All analyses were carried out on coded samples without knowledge of the patient’s clinical status.

Statistical Analysis.

Data were analyzed using statistical analysis software. Means and SDs were computed for continuous variables. The ORs and 95% confidence intervals were calculated to detect associations of variables with the p16INK4a methylation status of patients’ tumors. Multivariate analyses (logistic regression) were used to estimate the association of variables that were identified in univariate analyses with p16INK4a methylation. Significance levels of 0.05 were used for hypothesis testing.

Results

Patient Population and Molecular Approach for Detecting p16INK4a Methylation.

Patients in the present study were 120 consecutive incident cases of CRC ascertained through the University of Barcelona surgical services. As shown in Table 1<$REFLINK> , equal numbers of male and female patients were included in the series (50% male), with female patients showing an older age at presentation. The proportion of male cases from the larger hospital series (i.e., 53%) was somewhat, although not significantly, greater than the p16INK4a series. Population data from the Tarragona cancer registry, which is the closest regional registry to Barcelona, also indicate a greater proportion of male CRC; 57% of all incident CRCs in this region were male (1982–1995). The somewhat lower male:female ratio of CRC in our study may be due to the fact that men are less likely to undergo surgery; resection rates for rectal cancer, which is more common in men, are lower than for proximal CRC disease.

View this table:
  • View inline
  • View popup
Table 1

Demographic and clinical characteristics of the University of California, San Francisco-University of Barcelona CRC Study

Approximately 57% of the patients presented with Dukes’ stage C or D disease; this is similar to the proportion of such patients (50%) reported in a recent population-based case-control study in Majorca, Spain (32) . A higher proportion of women presented with advanced disease, which could represent a diagnostic delay. Histopathology results identified 12 (10%) cases whose tumors were classified as poorly differentiated. None of the patients reported a positive family history of early-onset CRC or multiple familial cases that might indicate a dominantly inherited CRC gene.

The multiplex MSPCR method was found to be highly specific and sensitive in the detection of methylated p16INK4a. DNA sequencing (data not shown) indicates that for methylated cell line DNA, all CpG sites within the amplified fragment were resistant to bisulfite conversion, whereas all cytosines at non-CpG sites were converted to thymidine residues. Only methylated PCR product was detected in the SW-480 cell line. Conversely, in the unmethylated cell line, all cytosines were converted to thymidine. Only unmethylated PCR product was detected in the SK-N-SH cell line. The MSPCR method, using 35 rounds of amplification, was capable of detecting 3% methylated template within a background of unmethylated DNA. Other studies (33) have validated the MSPCR approach by showing that it yields results that are fully concordant with other assays of p16INK4a methylation (e.g., restriction digest and Southern blot). Overall, 22 tumors were found to contain methylated p16INK4a. An unmethylated PCR product was detected in all tumors.

Clinicopathological Correlations with p16INK4a Methylation.

We used univariate analyses to explore correlations of clinical factors with p16INK4a methylation. Variables that had been previously identified as risk factors for anatomical and gender subtypes of CRC or that have prognostic importance were examined. Table 2<$REFLINK> shows the strong association of several of these factors with methylated p16INK4a. These factors were proximal location, advanced age, female gender, and poor histological differentiation. Stage was not associated with p16INK4a methylation status. To determine which of these factors was independently associated with p16INK4a methylation, a logistic regression analysis was carried out with the variables identified in the univariate comparisons. As shown in Table 3<$REFLINK> , proximal location, poor differentiation, and female gender remain statistically significant when included in this model; however, age was not a significant predictor. Fig. 1<$REFLINK> shows that women were much more likely than men to have methylated tumors and that proximal tumors were more likely to contain methylated p16INK4a. In Fig. 2<$REFLINK> , the p16INK4a methylation data are stratified according to the anatomical subsite of the CRCs. Although methylated tumors were dominant in cecal tumors and were common in cancers occurring in the ascending, transverse, and descending segments of the colon, methylation was very uncommon in tumors arising in the sigmoid, rectosigmoid colon, and rectum. Only 4 of 77 distal cancers had detectable p16INK4a methylation (Table 2)<$REFLINK> . The association of methylation with proximal location remained highly significant in the logistic regression when distal cases were defined as those occurring beyond the hepatic flexure (location, OR = 10.7; P < 0.002; female gender, OR = 6.5; P = 0.01).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Anatomical subsite distribution of p16INK4a methylation in CRC by gender. The histogram shows the percentage of tumors (n = 120) exhibiting p16INK4a methylation in the proximal (▪) and distal colon (▪) by gender. Numbers on bars are the percentage of methylated tumor for each subgroup. Proximal CRC includes the cecum, ascending, transverse, and descending segments; distal CRC includes the sigmoid, rectosigmoid, and rectal segments.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Anatomical subsite distribution of p16INK4a methylation in CRC for individual segments of the colorectum. Absolute numbers of tumors for each location are given in Table 1.<$REFLINK> ▪, percentages of subsite location of methylated tumors; ▪, percentages of subsite location of unmethylated tumors.

View this table:
  • View inline
  • View popup
Table 2

Clinical correlations of p16INK4a methylation in CRC in the University of California, San Francisco-University of Barcelona CRC Study

View this table:
  • View inline
  • View popup
Table 3

Logistic regression of p16INK4a methylation in the University of California, San Francisco-University of Barcelona CRC Study

Discussion

Methylation of p16INK4a is now recognized as a widespread epigenetic alteration in a variety of human cancers. We found that 18% of sporadic primary CRCs had detectable methylation of the 5′ region of the p16INK4a gene within a population of surgical CRC patients in Catalonia, Spain. A dramatic association of p16INK4a methylation was observed with proximal anatomical location of CRC in our series. Overall, proximal CRCs were 13-fold more likely to exhibit p16INK4a methylation than distal lesions. The highest prevalence of p16INK4a methylation was 64% among cecal tumors. An earlier study (26) reported that 20–60% of CRCs tested contained methylated p16INK4a; methylation was found to be more common in tumors exhibiting microsatellite instability compared with those that did not. It is not possible to compare the present results with those of the earlier report directly because that study included tumors selected for microsatellite instability. Our results are not dissimilar from that report because microsatellite instability was found in predominantly right-sided tumors (26) . In addition, our study found that female gender and poor histological differentiation were independently associated with p16INK4a methylation.

Taken together, the current results and previous epidemiological, clinical, and molecular evidence strongly indicate that distinct anatomical and gender-related subtypes of sporadic CRC exist (5 , 34 , 35) . It is of interest to compare our results on p16INK4a methylation with other molecular features of these subtypes; we note both overlap and divergence among the different genetic pathways. As shown here, an epigenetic pathway involving p16INK4a methylation dominates in proximal CRC in older women. The observation that microsatellite instability in sporadic CRC is far more common in the proximal versus distal colon and also shows a gender and age bias toward older women is similar to our observations (36) . Furthermore, high-grade microsatellite instability, which was recently observed in 16% of a large series of CRCs, is strongly associated with a loss of hMLH1 expression (36 , 37) . Although mutations in the hMLH1 gene are the most commonly known genetic change in HNPCC, they are not frequent (<25%) in sporadic CRC with microsatellite instability. Hence, methylation silencing is now thought to be the dominant mechanism for affecting hMLH1 in sporadic CRC (37, 38, 39, 40) and has an anatomical distribution similar to p16IN4a methylation. The consequence of deficient DNA mismatch repair, whether caused by mutation or transcriptional silencing, is thought to be the accumulation of mutations in critical genes containing simple repetitive sequences within their coding regions (e.g., transforming growth factor β receptor type II and insulin-like growth factor receptor type II). Although a large series of CRC patients has not yet been studied, preliminary evidence indicates that most type II transforming growth factor β and insulin-like growth factor receptor mutations occur in proximal colon tumors containing microsatellite instability (41, 42, 43) .

Another distinct subtype of CRC involves mutations in the p53 gene that occur dominantly in the distal colon and rectum (44) . A gender bias in mutant p53 has not been documented, but distal and particularly rectal CRC are well known to favor male gender. Mutations in codons 12 and 13 of the K-ras gene are also a common feature of CRC that may define yet another pathway in CRC genesis; the influences of anatomical location and gender in this pathway are not entirely clear. Although a meta-analysis of 2721 CRCs did not reveal an association of K-ras mutation with tumor location or gender (45) , other studies have reported a higher incidence of K-ras mutation in proximal cancers (46) and in proximal disease in younger women (<40 years) and older men (>90 years; Refs. 44 and 47 ).

Perhaps the most common alterations in CRC are those affecting the APC and DCC genes; these occur with high frequency (e.g., 70%) and have not been noted to occur preferentially in any anatomical location or gender group (48) . Thus, these alterations may also overlap several mechanisms of colon carcinogenesis. Interrelationships between methylation-driven mechanisms and those involving APC may be anticipated; however, based on observations in transgenic mice, tumorigenesis related to the APC gene is modified significantly by DNA methylation (49) . In addition, the APC gene promoter itself is a target of hypermethylation (50) .

The present results raise once again the intriguing and unresolved question of how female gender influences a specific pathway for CRC development. One of the earliest hypotheses addressing the role of anatomical subsite and gender in CRC postulated an influence of estrogen on bile acid secretion (17 , 18) . According to this hypothesis, estrogen, through its effect on serum cholesterol levels, affects the concentrations of secondary bile acids (e.g., deoxycholate), which have toxic, trophic, and promoting effects on the colonic epithelium. Diets high in animal fat and low in vegetables and fiber also increase bile secretion. A recent case-control study found that lower intake of vegetables and dietary fiber is a risk factor for proximal cancer specifically in older women and men (51) . In contrast, only limited evidence has been found to support a role for dietary factors thought to affect methylation (e.g., folate, B12, alcohol, and methinone intake; Ref. 52 ). There are clinical observations, however, that add to the biological plausibility of an etiological pathway operating within the proximal colon in women that involves aberrant DNA repair. For example, it has been noted that in HNPCC families, young women have about half the risk of men of developing CRC (53) . Our results indicate that the MSPCR method provides a powerful marker that future molecular epidemiological investigations can use to test specific hypotheses about estrogen, reproductive factors, diet, and CRC risk.

The unique anatomical distribution and gender bias found for p16INK4a methylation in our study indicate a distinct molecular pathway in CRC and provide important clues to the etiology of this subtype of sporadic CRC. Our a priori hypothesis concerning the point of anatomical division of proximal versus distal CRC (i.e., between the descending and sigmoid colon) was based on a large (38,931 cases) descriptive study of CRC that found this specific anatomical division to be correlated with secular increases in CRC risk within gender and ethnic subgroups (54) . We are aware, however, that several definitions of right- versus left-sided CRC have been proposed by different investigators. Among the considerations is the fact that the proximal and distal segments of the large intestine have different embryological origins (midgut versus hindgut, respectively) and vascular supplies (superior versus inferior mesenteric arteries). Interestingly, our data indicate an increased prevalence of p16INK4a methylation in CRCs up to the sigmoid colon and hence may provide a molecular correlate to the observed epidemiological differential in risk by gender. When we analyzed our data by redefining proximal CRC at the hepatic or splenic flexures, the location and gender associations with methylation remained highly significant. In addition, the anatomical distribution of CRC, and perhaps the associated methylation abnormalities, may be influenced by the source population of CRC. Spain has historically been a relatively low CRC risk country compared with other European countries or the United States. In recent decades, however, CRC incidence and mortality have increased markedly in Spain and have been accompanied by changes in dietary habits (55) .

In addition to being of significance in understanding the etiology of CRC, our results also have implications for the clinical management of CRC. The association of p16INK4a methylation with poorly differentiated tumors may indicate a more aggressive form of the disease. Also, it has been noted that as life expectancy increases in Westernized countries and the location of CRC is shifted toward more proximal cancers in older individuals, an increasing number of CRCs may not be detected with current screening practices (56) . Furthermore, these problems may be exaggerated in certain minority populations (6 , 7) . Future studies of the pathobiology of methylation silencing in colon carcinogenesis could help elucidate new screening and diagnostic approaches to target populations at high risk for anatomical and gender-specific subtypes of CRC. Finally, the aberrations of DNA methylation that are so common in some forms of CRC are potentially reversible alterations; hence, drug development targeting methylation could specifically aid in the treatment of populations now identified by anatomical location, gender, and ethnic characteristics (57) .

Footnotes

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • ↵1 Supported by the Foundation Marato (A. L., M. J. L.) and the National Institutes of Environmental Health Sciences NIH Grant P42-ESO4705 with funds provided by the Environmental Protection Agency (J. K. W., S. Z., C. G.).

  • ↵2 To whom requests for reprints should be addressed, at Laboratory for Molecular Epidemiology, Department of Epidemiology and Biostatistics, University of California San Francisco, 500 Parnassus Avenue, MU-W 420, San Francisco, CA 94143-0560.

  • ↵3 The abbreviations used are: CRC, colorectal cancer; MSPCR, methylation-specific PCR; APC, adenomatous polyposis coli; HNPCC, hereditary nonpolyposis colorectal cancer; OR, odds ratio.

    • Accepted April 7, 1999.
    • Received December 4, 1998.
    • Revision received March 15, 1999.

References

  1. ↵
    American Cancer Society. Cancer Facts and Figures, 1995 American Cancer Society Atlanta, GA 1995.
  2. ↵
    Shottenfeld D., Winewar S. J. Cancers of the large intestine Shottenfeld D. Fraumeni J. F. eds. . Cancer Epidemiology and Prevention, : 813-840, Oxford University Press New York 1996.
  3. ↵
    Haenszel W. Cancer mortality among the foreign born in the United States. J. Natl. Cancer Inst., 26: 37-132, 1961.
  4. ↵
    McMicheal A. J., Giles G. G. Cancer in migrants to Australia: extending the descriptive epidemiologic data. Cancer Res., 48: 751-756, 1988.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Potter J. D. Epidemiologic, environmental, and lifestyle issues in colorectal cancer Young G. P. Rozen P. Levin B. eds. . Prevention and Early Detection of Colorectal Cancer, : 23-44, WB Saunders London 1996.
  6. ↵
    Demers R. Y., Severson R. K., Shottenfeld D., Lazar L. Incidence of colorectal adenocarcinoma by anatomic subsite: an epidemiologic study of time trends and racial differences in the Detroit Michigan area. Cancer (Phila.), 79: 441-447, 1997.
    OpenUrlCrossRefPubMed
  7. ↵
    Chao A., Gilliland F., Hunt W. C., Bulterys M., Becker T. M., Key C. R. Increasing incidence of colon and rectal cancer among Hispanics and American Indians in New Mexico, 1969–1994. Cancer Causes Control, 9: 137-144, 1998.
    OpenUrlCrossRefPubMed
  8. ↵
    Kampman E., Potter J. D., Slattery M. L., Caan B. J., Edward S. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter case-control study in the United States. Cancer Causes Control, 8: 146-158, 1997.
    OpenUrlCrossRefPubMed
  9. ↵
    Grodstein F., Martinez M. E., Platz E. A., Giovannucci E., Colditz G. A., Kautzky M., Fuchs C., Stampfer M. J. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann. Intern. Med., 128: 705-712, 1998.
    OpenUrlPubMed
  10. ↵
    Potter J. D., Bostick R. M., Grandits G. A., Fosdick L., Elmer P., Wood J., Grambsch P., Louis T. A. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol. Biomark. Prev., 5: 770-784, 1996.
    OpenUrl
  11. ↵
    Chen M. J., Longnecker M. P., Morganstern H., Lee E. R., Frankl H. D., Haile R. W. Recent use of hormone replacement therapy and the prevalence of colorectal adenomas. Cancer Epidemiol. Biomark. Prev., 7: 227-230, 1998.
    OpenUrlAbstract
  12. ↵
    Butcher D., Hassanein K., Dudgeon M., Rhodes J., Holmes F. F. Female gender is a major determinant of changing subsite distribution of colorectal cancer with age. Cancer (Phila.), 56: 714-716, 1985.
    OpenUrlCrossRefPubMed
  13. ↵
    Vobecky J., Leduc C., Devroede G. Sex differences in the changing anatomic distribution of colorectal carcinoma. Cancer (Phila.), 54: 3065-3069, 1984.
    OpenUrlCrossRefPubMed
  14. ↵
    Alley P. G., McNee R. K. Age and sex differences in right colon cancer. Dis. Colon Rectum, 29: 227-229, 1986.
    OpenUrlPubMed
  15. ↵
    Dubrow R., Bernstein J., Holford T. R. Age-period-cohort modeling of large-bowel-cancer incidence by anatomic sub-site and sex in Connecticut. Int. J. Cancer, 53: 907-913, 1993.
    OpenUrlPubMed
  16. ↵
    Correa P., Haenszel W. The epidemiology of large bowel cancer. Adv. Cancer Res., 26: 2-141, 1978.
    OpenUrl
  17. ↵
    McMichael A. J., Potter J. D. Do intrinsic sex differences in lower alimentary tract physiology influence the sex-specific risks for bowel cancer and other biliary and intestinal diseases?. Am. J. Epidemiol., 118: 620-627, 1983.
    OpenUrlFREE Full Text
  18. ↵
    McMicheal A. J., Potter J. D. Host factors in carcinogenesis: certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. J. Natl. Cancer Inst., 75: 185-191, 1985.
  19. ↵
    Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 61: 759-767, 1990.
    OpenUrlCrossRefPubMed
  20. ↵
    Lasky T., Silbergeld E. P53 mutations associated with breast, colorectal, liver, lung and ovarian cancer. Environ. Health Perspect., 104: 1324-1331, 1996.
    OpenUrlPubMed
  21. ↵
    O’Sullivan M. J., McCarthy T. V., Doyle C. T. Familial adenomatous polyposis: from bedside to benchside. Am. J. Clin. Pathol., 109: 521-526, 1998.
    OpenUrlPubMed
  22. ↵
    Marra G., Boldand C. R. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes and historical perspective. J. Natl. Cancer Inst., 87: 1114-1125, 1995.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Olschwang S., Hamelin R., Laurent-Puig P., Thuille B., De Rycke Y., Li Y. J., Muzeau F., Girodet J., Salmon R. J., Thomas G. Alternative genetic pathways in colorectal carcinogenesis. Proc. Natl. Acad. Sci. USA, 94: 12122-12127, 1997.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Zingg J. M., Jones P. A. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis (Lond.), 18: 869-882, 1997.
    OpenUrlFREE Full Text
  25. ↵
    Herman J. G., Merlo A., Mao L., Lapidus R. G., Issa J. P. J., Davidson N. E., Sidransky D., Baylin S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Ahuja N., Mohan A. L., Li Q., Stolker J. M., Herman J. G., Hamilton S. R., Baylin S. B., Issa J. P. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res., 57: 3370-3374, 1997.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Serrano M. The tumor suppressor protein p16INK4a. Exp. Cell Res., 237: 7-13, 1997.
    OpenUrlCrossRefPubMed
  28. ↵
    Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5′ CPG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
    OpenUrlCrossRefPubMed
  29. ↵
    Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., Van Tomout J. M., Jones P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Clark S. J., Harrison J., Paul C. L., Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res., 22: 2990-2997, 1994.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Bautista D., Obrador A., Moreno V., Cabeza E., Canet R., Benito E., Bosch X., Costa J. Ki-ras mutation modifies the protective effect of dietary monounsatruated fat and calcium on sporadic colorectal cancer. Cancer Epidemiol. Biomark. Prev., 6: 57-61, 1997.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Gonzalgo M. L., Bender C. M., You E. H., Glendening J. M., Flores J. F., Walker G. J., Hayward N. K., Jones P. A., Fountain J. W. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approach for methylation analysis of primary tumors. Cancer Res., 57: 5336-5347, 1997.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Bulfill J. A. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann. Intern. Med., 113: 779-788, 1990.
  35. ↵
    Distler P., Holt P. R. Are right and left-sided colon neoplasms distinct tumors?. Dig. Dis., 15: 302-311, 1997.
    OpenUrlCrossRefPubMed
  36. ↵
    Thibodeau S. N., French A. J., Cunningham J. M., Tester D., Burgart L. J., Roche P. C., McDonnell S. K., Schaid D. J., Vockley C. W., Michels V. V., Farr G. H. Jr., O’Connell M. J. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res., 58: 1713-1718, 1998.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Cunningham J. M., Christensen E. R., Tester D. J., Kim C. Y., Roche P. C., Burgart L. J., Thibodeau S. N. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res., 58: 3455-3460, 1998.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Kane M. F., Loda M., Gaida G. M., Lipman J., Mishra R., Goldman H., Jessup J. M., Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res., 57: 808-811, 1997.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    Veigl M. L., Kasturi L., Olechnowicz J., Ma A. H., Lutterbaugh J. D., Periyasamy S., Li G. M., Drummond J., Modrich P. L., Sedwick W. D., Markowitz S. D. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. USA, 95: 8698-8702, 1998.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Herman J. G., Umar A., Polyak K., Graff J. R., Ahuja N., Issa J. P., Markowitz S., Willson J. K., Hamilton S. R., Kinzler K. W., Kane M. F., Kolodner R. D., Vogelstein B., Kunkel T. A., Baylin S. B. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Akiyama Y., Iwanaga R., Ishikawa T., Sakamoto K., Nishi N., Nihei Z., Iwama T., Saitoh K., Yuasa Y. Mutations of the transforming growth factor-β type II receptor gene are strongly related to sporadic proximal colon carcinoma with microsatellite instability. Cancer (Phila.), 78: 2478-2485, 1996.
    OpenUrlCrossRefPubMed
  42. ↵
    Togo G., Toda N., Kanai F., Kato N., Shiratori Y., Kishi K., Imazeki F., Makuuchi M., Omata M. A transforming growth factor B type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability. Cancer Res., 56: 5620-5623, 1996.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Souza R. F., Appel R., Yin J., Wang S., Smolinski K. N., Abraham J. M., Zou T. T., Shi Y. Q., Lei J., Cottrell J., Cymes K., Biden K., Simms L., Leggett B., Lynch P. M., Frazier M., Powell S. M., Harpaz N., Sugimura H., Young J., Meltzer S. J. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat. Genet., 14: 255-257, 1996.
    OpenUrlCrossRefPubMed
  44. ↵
    Breivik J., Loth R. A., Melin G. I., Rognum T. O., Borresen-Dale A. L., Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int. J. Cancer, 74: 664-669, 1997.
    OpenUrlCrossRefPubMed
  45. ↵
    Andreyev H. J. N., Norman A. R., Cunningham D., Oates J. R., Clarkes P. A. Kirsten ras mutation in patients with colorectal cancer: the multicenter “RASCAL” study. J. Natl. Cancer Inst., 90: 675-684, 1998.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Elnatan J., Goh H. S., Smith D. R. c-Ki-ras activation and the biological behavior of proximal and distal colonic adenocarcinoma. Eur. J. Cancer, 32A: 491-497, 1996.
    OpenUrlCrossRef
  47. ↵
    Breivik J., Meling G. I., Spurkland A., Rognum T. O., Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br. J. Cancer, 69: 367-371, 1994.
    OpenUrlPubMed
  48. ↵
    Gryfe R., Swallow C., Bapat B., Redston M., Gallinger S., Couture J. Molecular biology of colorectal cancer. Curr. Probl. Cancer, 21: 233-300, 1997.
    OpenUrlCrossRefPubMed
  49. ↵
    Laird P. W., Jackson-Grusby L., Fazeli A., Dickinson S. L., Jung W. E., Li E., Weinberg R. A., Jaenisch R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell, 81: 197-205, 1995.
    OpenUrlCrossRefPubMed
  50. ↵
    Hiltunen M. O., Alhonen L., Koistinaho J., Myohanen S., Paakkonen M., Marin S., Kosma V. M., Janne J. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int. J. Cancer, 70: 644-648, 1997.
    OpenUrlCrossRefPubMed
  51. ↵
    Slattery M. L., Potter J. D., Coates A., Ma K. N., Berry T. D., Duncan D. M., Caan B. J. Plant foods and colon cancer: an assessment of specific foods and their related nutrients. Cancer Causes Control, 8: 575-590, 1997.
    OpenUrlCrossRefPubMed
  52. ↵
    Slattery M. L., Schaffer D., Edwards S. L., Ma K. N., Potter J. D. Are dietary factors involved in DNA methylation associated with colon cancer?. Nutr. Cancer, 28: 52-62, 1997.
    OpenUrlPubMed
  53. ↵
    Gaglia P., Atkin W. S., Whitelaw S., Talbot I. C., Williams C. B., Norhover J. M., Hodgson S. V. Variables associated with the risk of colorectal adenomas in asymptomatic patients with a family history of colorectal cancer. Gut, 36: 385-390, 1995.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    Nelson R. L., Dollear T., Freels S., Persky V. The relation of age, race, gender to the subsite location of colorectal carcinoma. Cancer (Phila.), 801: 193-197, 1997.
    OpenUrl
  55. ↵
    Lopez-Abente G., Pollan M., Vergara A., Moreno C., Moreo P., Ardanaz E., Aragones N. Age-period-cohort modeling of colorectal cancer incidence and mortality in Spain. Cancer Epidemiol. Biomark. Prev., 6: 999-1005, 1997.
    OpenUrlAbstract
  56. ↵
    Cooper G. S., Yuan Z., Landefeld C. S., Johanson J. F., Rimm A. A. A national population-based study of incidence of colorectal cancer and age. Implications for screening older Americans. Cancer (Phila.), 75: 775-781, 1995.
    OpenUrlCrossRefPubMed
  57. ↵
    Zingg J. M., Jones P. A. DNA methylation as a target for drug design. Pharm. Res. (NY), 15: 175-187, 1998.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
June 1999
Volume 8, Issue 6
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Aberrant Methylation of p16INK4a in Anatomic and Gender-specific Subtypes of Sporadic Colorectal Cancer
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Aberrant Methylation of p16INK4a in Anatomic and Gender-specific Subtypes of Sporadic Colorectal Cancer
John K. Wiencke, Shichun Zheng, Amalia Lafuente, Maria Jose Lafuente, Corita Grudzen, Margaret R. Wrensch, Rei Miike, Antonio Ballesta and Manuel Trias
Cancer Epidemiol Biomarkers Prev June 1 1999 (8) (6) 501-506;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Aberrant Methylation of p16INK4a in Anatomic and Gender-specific Subtypes of Sporadic Colorectal Cancer
John K. Wiencke, Shichun Zheng, Amalia Lafuente, Maria Jose Lafuente, Corita Grudzen, Margaret R. Wrensch, Rei Miike, Antonio Ballesta and Manuel Trias
Cancer Epidemiol Biomarkers Prev June 1 1999 (8) (6) 501-506;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Urinary Melatonin in Relation to Breast Cancer Risk
  • Endometrial Cancer and Ovarian Cancer Cross-Cancer GWAS
  • Risk Factors of Subsequent CNS Tumor after Pediatric Cancer
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement